These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 3640792)

  • 1. In vitro suppression of HTLV-III/LAV infectivity by a combination of acyclovir and suramin.
    Resnick L; Markham PD; Veren K; Salahuddin SZ; Gallo RC
    J Infect Dis; 1986 Dec; 154(6):1027-30. PubMed ID: 3640792
    [No Abstract]   [Full Text] [Related]  

  • 2. Suramin in the treatment of AIDS: mechanism of action.
    De Clercq E
    Antiviral Res; 1987 Jan; 7(1):1-10. PubMed ID: 2432836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative inhibitory effects of suramin and other selected compounds on the infectivity and replication of human T-cell lymphotropic virus (HTLV-III)/lymphadenopathy-associated virus (LAV).
    Balzarini J; Mitsuya H; De Clercq E; Broder S
    Int J Cancer; 1986 Mar; 37(3):451-7. PubMed ID: 2419266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of suramin on HTLV-III/LAV infection presenting as Kaposi's sarcoma or AIDS-related complex: clinical pharmacology and suppression of virus replication in vivo.
    Broder S; Yarchoan R; Collins JM; Lane HC; Markham PD; Klecker RW; Redfield RR; Mitsuya H; Hoth DF; Gelmann E
    Lancet; 1985 Sep; 2(8456):627-30. PubMed ID: 2863631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implications of the discovery of HTLV-III for the treatment of AIDS.
    Yarchoan R; Mitsuya H; Matsushita S; Broder S
    Cancer Res; 1985 Sep; 45(9 Suppl):4685s-4688s. PubMed ID: 2410113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical pharmacokinetics of suramin in patients with HTLV-III/LAV infection.
    Collins JM; Klecker RW; Yarchoan R; Lane HC; Fauci AS; Redfield RR; Broder S; Myers CE
    J Clin Pharmacol; 1986 Jan; 26(1):22-6. PubMed ID: 3005375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protection of T cells against infectivity and cytopathic effect of HTLV-III in vitro.
    Mitsuya H; Matsushita S; Yarchoan R; Broder S
    Princess Takamatsu Symp; 1984; 15():277-88. PubMed ID: 6085846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiviral activity of the polybasic anion, suramin and acyclovir in Hepadna virus infection.
    Tsiquaye KN; Collins P; Zuckerman AJ
    J Antimicrob Chemother; 1986 Oct; 18 Suppl B():223-8. PubMed ID: 3793662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human alpha- and beta-interferon but not gamma- suppress the in vitro replication of LAV, HTLV-III, and ARV-2.
    Yamamoto JK; Barré-Sinoussi F; Bolton V; Pedersen NC; Gardner MB
    J Interferon Res; 1986 Apr; 6(2):143-52. PubMed ID: 2425014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New combinations beat HIV in vitro.
    Nurs Stand; 1993 Mar 17-23; 7(26):17. PubMed ID: 8481305
    [No Abstract]   [Full Text] [Related]  

  • 11. Lack of response to suramin in patients with AIDS and AIDS-related complex.
    Kaplan LD; Wolfe PR; Volberding PA; Feorino P; Levy JA; Abrams DI; Kiprov D; Wong R; Kaufman L; Gottlieb MS
    Am J Med; 1987 Mar; 82(3 Spec No):615-20. PubMed ID: 3548350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitors of retroviral DNA polymerase: their implication in the treatment of AIDS.
    Chandra P; Vogel A; Gerber T
    Cancer Res; 1985 Sep; 45(9 Suppl):4677s-4684s. PubMed ID: 2410112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiviral chemotherapy against HTLV-III/LAV infections.
    Oberg B
    J Antimicrob Chemother; 1986 May; 17(5):549-52. PubMed ID: 2424886
    [No Abstract]   [Full Text] [Related]  

  • 14. AIDS update: HTLV-III/LAV infection.
    Cassens BJ
    Pa Med; 1986 Jan; 89(1):24-6. PubMed ID: 3005945
    [No Abstract]   [Full Text] [Related]  

  • 15. Acyclovir improves survival.
    AIDS Patient Care; 1994 Jun; 8(3):165. PubMed ID: 11362142
    [No Abstract]   [Full Text] [Related]  

  • 16. Low concentrations of suramin can reduce in vitro infection of human cord blood lymphocytes with HTLV-I during long-term culture.
    Pesce CD; Ciprani F; D'Onofrio C; Alvino E; Perno CF; Bonmassar E; Caliò R
    Antiviral Res; 1987 Dec; 8(5-6):247-60. PubMed ID: 2897831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of HTLV-III/LAV-infected patients with D-penicillamine.
    Schulof RS; Scheib RG; Parenti DM; Simon GL; DiGioia RA; Paxton HM; Sztein MB; Chandra P; Courtless JW; Taguchi YT
    Arzneimittelforschung; 1986 Oct; 36(10):1531-4. PubMed ID: 2949756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amplification of HTLV-III/LAV infection by antigen-induced activation of T cells and direct suppression by virus of lymphocyte blastogenic responses.
    Margolick JB; Volkman DJ; Folks TM; Fauci AS
    J Immunol; 1987 Mar; 138(6):1719-23. PubMed ID: 3493285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Protease inhibitors are effective only on HIV-infected cells].
    Fortschr Med; 1996 May; 114(15):12. PubMed ID: 8767934
    [No Abstract]   [Full Text] [Related]  

  • 20. Inhibition of infectivity and replication of HIV-2 and SIV in helper T-cells by 2',3'-dideoxynucleosides in vitro.
    Mitsuya H; Broder S
    AIDS Res Hum Retroviruses; 1988 Apr; 4(2):107-13. PubMed ID: 2835072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.